Novavax Inc stock (US66987V1098): NVAX trades at $11.09 on Nasdaq

Novavax shares were last quoted at $11.09 on Nasdaq, with market data showing a $1.82 billion market value and heavy short interest as of late May 2026.

Novavax shares closed or last traded at $11.09 on Nasdaq, and MarketBeat also pegged the company's market cap at $1.82 billion with volume of 9.77 million shares on the latest close. In Germany, the stock was also visible on Tradegate-style quote services at around the same level, keeping the U.S.-listed vaccine maker on the radar of home-market investors and international traders alike.

As of: 05/28/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: NVAX
• Sector/industry: Biotechnology, vaccines
• Headquarters/country: Gaithersburg, United States
• Core markets: United States, Europe and other international vaccine markets
• Key revenue drivers: Novavax vaccine sales, licensing and collaboration revenue
• Home exchange/listing venue: Nasdaq (NVAX)
• Trading currency: USD

Novavax Inc: core business model

Novavax develops protein-based vaccines and earns revenue mainly from product sales and partnership-related income tied to its vaccine portfolio.

Industry trends and competitive position

Short interest remained a key market feature in May 2026: MarketBeat said 45.28 million shares were sold short as of 05/15/2026, equal to 27.81% of the public float, after a previous reading of 49.48 million shares as of 04/30/2026. That still leaves NVAX among the more heavily shorted U.S.-listed biotech names, a setup that can amplify trading swings when new data or commercial updates hit the tape.

Market data from MarketScreener showed NVAX at $10.11 with a 9.53% daily gain and a 50.45% move over a longer period, underscoring how quickly sentiment can shift around a small-cap vaccine stock listed on Nasdaq in the United States. The same quote page listed US6700024010, while the company remains tied to U.S. market trading and dollar-denominated pricing.

Novavax remains a vaccine-focused biotech rather than a diversified pharmaceutical group, and its results are typically shaped by product demand, licensing deals and the pace of new commercial agreements.

Conclusion

NVAX enters the latest trading day with price action, short interest and biotech-sector sentiment still doing much of the work for investors. The Nasdaq listing and U.S. home-market context remain central to how the stock is read, while the elevated short base keeps attention on any fresh company-specific catalyst.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.